報價延遲最少15分鐘:2025/08/25 16:58 EDT
盤後時段
|
||||
|
4.11 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.11
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.05/0.12
|
|
企業價值
536.58M
|
| 資產負債 |
|
每股賬面淨值
2.97
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
200.45M
|
|
每股收益
1.38
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/25 16:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. ItsFSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States. |
